NIGP 26924: Cardiovascular Drugs

NIGP 26924 Cardiovascular Drugs, an Item code, encompasses specific cardiac and hemodynamic medications that state and local governments procure for emergency medical services, hospital systems, and health benefit programs. Recent solicitations show concrete demand for injectable cardiovascular agents including epinephrine, labetalol, adenosine, and diltiazem—drugs administered in advanced life support protocols by fire rescue and EMS services. The work involves supply of finished pharmaceutical products meeting strict expiration and quality standards, with vendors responsible for shipping, inventory management, replacement of expired stock, and full compliance with OSHA and federal accessibility requirements. Issuing bodies include city purchasing departments operating on behalf of municipal fire rescue services and state health and human services commissions managing pharmacy benefit and direct-to-manufacturer prescription initiatives.

Recent activity spans Florida and Texas. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications for Tampa Fire Rescue, requesting 370 units of Labetalol HCl 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with a response deadline of April 8, 2026 and estimated contract value of $40,000.00; the award carried a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount for SLBE participation. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity to contract outside traditional pharmacy benefit manager and group purchasing organization channels—a preliminary information-gathering step preceding formal procurement. The Tampa solicitation demonstrates immediate operational demand from municipal emergency services; the Texas RFI signals emerging state-level interest in alternative pharmaceutical supply and contracting models.